trial failure

Showing 8 posts of 38 posts found.


Biogen halts Tysabri trial after failure in acute ischemic stroke

February 8, 2018
Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …


FDA halts Bellicum trial over brain disease in participants, shares crash 48%

February 1, 2018
Research and Development Bellicum Pharmaceuticals, FDA, encephalopathy, pharma, trial failure

Texas-based clinical-stage company Bellicum Pharmaceuticals has taken a massive stock hit after the FDA put a hold on its trials …


Galectin Therapeutics’ share value plummets by half after NASH drug failure

December 6, 2017
Research and Development Galectin Therapeutics, nash, pharma, trial failure

Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis …


Stem cell therapy fails to improve symptoms of peripheral artery disease

November 16, 2017
Research and Development Stem cells, peripheral artery disease, pharma, stem cell therapy, trial failure

A new study has revealed that a promising stem cell therapy failed to improve ability to walk in patients with …


Amicus pulls plug on rare skin disease drug after Phase 3 failure

September 14, 2017
Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure

New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …


AZ “disappointment” at heart drug failure

October 5, 2016
Research and Development AZ, AstraZeneca, trial failure

AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …


AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again

August 9, 2016
Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure

AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …


Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals

June 15, 2016
Research and Development, Sales and Marketing AbbVie, infinity pharmaceuticals, non-Hodgkin lymphoma, trial failure

Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …

Latest content